Tobira Therapeutics, Inc. (TBRA): A/s Novo , 10% owner of Tobira Therapeutics, Inc. sold 66,814 shares on Jun 28, 2016. The Insider selling transaction was reported by the company on Jun 30, 2016 to the Securities and Exchange Commission. The shares were sold at $13.32 per share for a total value of $870,940.88 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 7, 2016, A/s Novo (10% owner) sold 187,500 shares at $10.37 per share price.
Shares of Tobira Therapeutics Inc (TBRA) ended Wednesday, Jun 29, 2016 session in red amid volatile trading. The shares closed down -0.78 points or -5.88% at $12.49 with 97,509 shares getting traded. Post opening the session at $13.42, the shares hit an intraday low of $12.14 and an intraday high of $13.42 and the price vacillated in this range throughout the day. The company has a market cap of $235 M and the number of outstanding shares has been calculated to be 1,88,15,689 shares. The 52-week high of Tobira Therapeutics Inc is $19.56 and the 52-week low is $6.085.
Company has been under the radar of several Street Analysts.Tobira Therapeutics Inc is Initiated by H.C. Wainwright to Buy and the brokerage firm has set the Price Target at $22. The Rating was issued on Apr 11, 2016.
Tobira Therapeutics Inc. formerly Regado BioSciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease inflammation fibrosis and human immunodeficiency virus (HIV). The Companys lead product candidate cenicriviroc (CVC) is an immunomodulator that can be used to treat a number of diseases including non-alcoholic steatohepatitis (NASH) kidney fibrosis HIV-1 and others. The Company is engaged in clinical studies for CVC including the CENTAUR Study an international randomized Phase IIb study of CVC and placebo in patients with NASH and liver fibrosis (NCT02217475). The Company has initiated ORION a Phase IIa Study of Cenicriviroc in obese patients with fatty liver disease. It is also engaged in the Phase I pioglitazone safety combination study. NASH is a type of non-alcoholic fatty liver disease or NAFLD. NAFLD is a liver disease and is associated with obesity and type-2 diabetes.